Conference on Retroviruses and Opportunistic Infections (CROI), February 13-16, 2017, Seattle WA

Conference Reports for NATAP


CROI 2017 - Conference on Retroviruses and Opportunistic Infections (CROI) February 13-16, 2017, Seattle WA

	Frailty, Bones, and Vitamin D: CROI 2017 - Todd T. Brown, MD, PhD Professor of Medicine and Epidemiology Johns Hopkins University - (04/06/17) HIV Prevention at CROI 2017 Conference on Retroviruses and Opportunistic Infections - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/23/17) CROI Summary 2017: Antiretroviral treatment - where we are now / New HIV Drugs & Treatments - Joseph J. Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/06/17) The Kidney at CROI 2017 - written by - Christina Wyatt MD - Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY (03/01/17) CROI 2017: Better Living with HIV Infection - written by - David Alain Wohl, MD - The University of North Carolina at Chapel Hill (03/01/17) Impressions of CROI 2017 - written by- Pablo Tebas, MD University of Pennsylvania - (03/01/17) Clinical Pharmacology at CROI 2017 - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (03/13/17) Summary from CROI 2017 for Viral Hepatitis HCV - elimination on its way: dream or emerging reality? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/22/17) Cardiovascular Update from CROI 2017 - by Priscilla Hsue MD Professor of Medicine, UCSF - (05/16/17) Predictors of Severe Weight/Body Mass Index Gain Following Antiretroviral Initiation - (05/8/18) HIV Cancer at CROI 2017 - (02/02/18) Key Select Aging & HIV Reports 2 An entire section on the NATAP website devoted to Aging & HIV. - (06/07/17) Key Aging / HIV Reports 1 of 2 NATAP website devoted to Aging & HIV - (06/07/17) Aerobic Interval Training Versus Continuous Moderate Exercise as a Treatment for the Metabolic Syndrome - (06/07/17) CURE at CROI 2017 - (07/22/17) Types of ischemic strokes among HIV-infected individuals across the United States - (06/07/17) Peripheral endothelial function is suboptimal in HCV-untreated, HIV-suppressed adults - - (05/09/17) Cataloguing the Impact of Y93 Substitutions on HCV NS5A Inhibitor Susceptibility - - (05/03/17) Identification of HCV Inter-Subtype Recombinant Strains with Breakpoint in NS5A - - (05/03/17) Higher Carnitine Tied to Almost Quintupled MI Risk in People With HIV Conference on Retroviruses and Opportunistic Infections (CROI), February 13-16, 2017, Seattle - Mark Mascolini - (05/01/17) CROI 2017 Summary Report - A lot Going On - good Conference with Lots of New Information - New HIV Drugs, Aging/Comorbidities, Cure & PrEP, Fatty Liver/HCV-HBV - - (04/19/17) PHARMACOKINETICS OF RILPIVIRINE AFTER SWITCHING FROM EFAVIRENZ IN ADOLESCENTS - - (04/18/17) Predictors of Severe Weight/Body Mass Index Gain Following Antiretroviral Initiation - - (04/18/17) Pharmacokinetics, Safety, and Efficacy of Atazanavir or Darunavir With Cobicistat in Adolescents (12 to <18 years of age) - - (04/18/17) PHARMACOKINETICS OF RILPIVIRINE AFTER SWITCHING FROM EFAVIRENZ IN ADOLESCENTS - - (04/17/17) Substantially Lower Rilpivirine Plasma Concentrations during Pregnancy - - (04/17/17) Low HIV-1 Resistance in Subjects Using Darunavir Once-daily Regimens Across Studies - - (04/17/17) EXERCISE, OXIDATIVE STRESS AND FIBRINOLYTIC FUNCTION IN HIV-1 INFECTED ADULTS - - (04/17/17) Blood Brain Barrier function, ART neuroactivity and risk of CSF HIV escape / BBB Permeability & Neurocognitive Performance in HIV+ - - (04/12/17) DEVELOPMENT OF A PKC AGONIST DERIVED FROM INGENOL FOR HIV LATENCY DISRUPTION IN VIVO - - (04/12/17) FATTY LIVER DISEASE: A GROWING CONCERN - - (04/12/17) CROI: Neurocognitive Disorders - Neurologic, Brain, Cognitive Impairment - - (04/10/17) Ledipasvir/Sofosbuvir Raises Tenofovir Diphosphate Concentrations in Red Cells - - (04/10/17) HIV Infection and the Occurrence of Medically Significant Falls: Accelerated or Accentuated Aging? - - (04/06/17) A RANDOMIZED TRIAL OF VITAMIN D3 (3000 VERSUS 1000 IU) IN HIV+ POSTMENOPAUSAL WOMEN - - (04/06/17) VITAMIN D DEFICIENCY IMPAIRS THE BENEFICIAL EFFECTS OF STATIN IN TREATED HIV - - (04/06/17) HIGH DOSE VITAMIN D3 INCREASES SPINE BONE DENSITY IN HIV+ YOUTH ON TENOFOVIR (TDF) - - (04/06/17) Switching from TDF To TAF in HIV-Infected Adults With Low BMD: A Pooled Analysis - - (04/05/17) Frailty Status and Risk of Falls in HIV-Infected Older Adults in the ACTG A5322 Study - - (04/05/17) Antiretroviral-induced Bone Loss is Durably Suppressed by A Single Dose of Zoledronic Acid - - (04/05/17) CROI 2017 HCV/HBV Reports - - (04/05/17) Ledipasvir/Sofosbuvir Raises Tenofovir Diphosphate Concentrations in Red Cells - - (04/04/17) Acute HCV Drops Sharply in HIV-Positive Dutch MSM After DAA Rollout - Mark Mascolini - (04/04/17) Acute HCV Drops Sharply in HIV-Positive Dutch MSM After DAA Rollout - Mark Mascolini - (03/31/17) "Hooked on painkillers" before first injection among PWID in 16 US cities - CDC - (03/31/17) HIV Awareness/Care in US Black Men May Explain Less HIV in Black Women - Mark Mascolini - (03/31/17) New HIV Drugs at CROI / CROI Antiretroviral Treatment Summary / Long Acting HIV Therapies - (03/31/17) Body Mass Index and the Risk of Serious Non-AIDS Events - Mark Mascolini - (03/31/17) Rilpivirine Injected Every 8 Weeks Maintains Adequate Levels in Women: HPTN 076 - Mark Mascolini - (03/31/17) Use of Cocaine, Meth, Opioids Remains High in US MSM: 2008-2014 - Mark Mascolini - (03/30/17) COPD Markers Linked to Tripled Mortality Risk in People With HIV - Mark Mascolini - (03/30/17) Dapivirine Vaginal Ring Does Not Blunt Effectiveness of Hormonal Contraception - Mark Mascolini - (03/30/17) TREND IN MULTIMORBIDITY AMONG HIV+ ADULTS IN CLINICAL CARE IN THE US - (03/29/17) MRS Measures Associate with Impaired Neuropsychological Performance in Acute HIV - (03/29/17) P2X receptors as therapeutic targets of HIV-1 infection and inflammation - (03/29/17) LONG-TERM EFFECTS OF IMMEDIATE VERSUS DEFERRED cART IN PRIMARY HIV INFECTION - (03/29/17) Prevalence of neurocognitive disorders in a well-treated and aging Swiss HIV Cohort - (03/29/17) Benefit of continuous/immediate ART on disease risk: SMART & START combined analysis - (03/29/17) ART in HIV persons with pre-treatment viremia <3000c/mL: the START study - (03/29/17) INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPH NODE AND GUT MUCOSAL TISSUE - (03/29/17) Changes In Liver Steatosis After Switching Efavirenz To Raltegravir: The STERAL Study - (03/29/17) Multiple-Dose Treatment With Ritonavir Increases the Exposure of Doravirine - (03/29/17) Raltegravir Switch and Biomarkers of Liver Steatosis and Metabolic Syndrome in Women - (03/29/17) Changes in Liver Fibrosis and Steatosis in HIV Mono-Infected patients over 24 months - 50% have fatty liver at average age of 46 - (03/28/17) LIVER STEATOSIS AND FIBROSIS IN AT-RISK EUROPEAN HIV-MONOINFECTED PATIENTS - 64% with steatosis among those who had elevated LFTs and/or metabolic syndrome and/or lipodystrophy - (03/28/17) FATTY LIVER DISEASE: A GROWING CONCERN - highly recommended - (03/28/17) Emergence of Integrase Resistance Mutations During Initial Therapy with TDF/FTC/DTG - (03/27/17) IFN-FREE THERAPY IS EFFECTIVE AND SAFE FOR HCV RECURRENCE IN LT HCV/HIV CO-INFECTION - (03/23/17) Effectiveness of DAAs In HIV/HCV-coinfected Patients with Decompensated Cirrhosis - (03/23/17) Efficacy and Safety of Direct Antiviral Agents in Cirrhotic HCV-HIV Coinfected Patients - (03/23/17) Cost of noninfectious comorbidities in patients with HIV - Cost of HIV CARE Increases 5 fold Due to Cost for Comorbidities from <40 to >60 - (03/23/17) - (03/23/17) Frailty Status and Risk of Falls in HIV-Infected Older Adults in the ACTG A5322 Study - (03/22/17) STI Incidence among MSM Following HIV Preexposure Prophylaxis: A Modeling Study / Quarterly STI Screening Reduced STIs by 50% -Model - (03/22/17) High Efficacy of IFN-free Anti-HCV Regimens for Individuals on Opiate Agonist Therapy - (03/22/17) TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP) - (03/22/17) INCREASED RATES OF HBV SEROCONVERSION UNDER LONG-TERM HBV ACTIVE THERAPY IN HBV/HIV - [16%] - (03/22/17) REAL-LIFE TREATMENT RATES FOR HEPATOCELLULAR CARCINOMA IN HIV-INFECTED PATIENTS - (03/21/17) High Efficacy of IFN-free Anti-HCV Regimens for Individuals on Opiate Agonist Therapy - (03/21/17) High Efficacy of IFN-free Anti-HCV Regimens for Individuals on Opiate Agonist Therapy - (03/21/17) 95% SVR Rates Using Imported Generic DAAs for Patients With Hepatitis C - (03/21/17) Delivering HCV Cures in the FQHC Medical Home: Training a New Generation of Providers - (03/21/17) Strategies for Utilizing Electronic Health Record to Improve Birth Cohort Testing In the Hospital Setting - (03/21/17) Implementation of an EHR Prompt Reveals Low Adherence to HCV Birth Cohort Testing Recommendations - (03/21/17) Similar SVR12 cure rates for patients treated for hepatitis C in FQHCs with behavioral health conditions compared to those without - (03/21/17) HCV TREATMENT IN PEOPLE WHO INJECT DRUGS CO-LOCATED WITHIN A NEEDLE SYRINGE PROGRAM - (03/21/17) Cost-effectiveness of HCV Screening and Linkage in MMT: Relevance of HIV Co-infection - (03/20/17) Real-world outcomes of HCV treatment in homeless and marginally housed adults - (03/20/17) HCV REINFECTION AFTER SUCCESFUL DAA TREATMENT -A GECCO ANALYSIS - 11% HIV+ MSM - (03/20/17) Direct-Acting Antivirals Improve Access to Care and Cure for Patients with HIV and chronic Hepatitis C Virus from 2011-2015 - (03/20/17) High rates of hepatitis C virus cure among black and non-black persons with HIV-infection receiving care in an urban center - (03/20/17) Same same but different? Risk of DAA therapy failure in real-life HCV/HIV coinfection: The GECCO Cohort - (03/20/17) HIV-HCV Coinfection in the DAA Era: "En Route for Eradication" ? - (03/20/17) Effectiveness of All-Oral DAAs for HCV Genotype 3 In HIV/HCV-Coinfected Patients - (03/20/17) Resistance emergence in macaques administered Cabotegravir long-acting (CAB LA) during acute infection - (03/20/17) Concordant Population-level Increases in PrEP Found with Novel Public Health Methods - (03/20/17) STD PARTNER SERVICES TO MONITOR AND PROMOTE PREP USE AMONG MEN WHO HAVE SEX WITH MEN - (03/20/17) Text Messaging is Associated with Improved Retention in a Clinic-based PrEP Program - (03/20/17) MIDWEST PHARMACISTS' KNOWLEDGE OF & WILLINGNESS TO PROVIDE PRE-EXPOSURE PROPHYLAXIS - (03/20/17) Physical Function and Inflammation in Older HIV-Infected Men - (03/16/17) Exhausted T-cells and Inflammatory Monocytes are Linked to Brain Atrophy in HIV - (03/10/17) Impact of smoking, hypertension, and cholesterol on myocardial infarction in HIV-infected adults...."hypertension, cholesterol & smoking are very strong drivers of MIs in HIV+" - (03/10/17) Older Age Associated with both Adherence and Renal Decline in the PrEP Demo Project - (03/10/17) Bone Changes With TDF-containing and Non-TDF-containing (maraviroc) Prep in U.S. Men and Women - (03/10/17) IMPACT OF VAGINAL MICROBIOTA ON GENITAL TISSUE AND PLASMA CONCENTRATIONS OF TENOFOVIR - (03/10/17) Brief Behavioral Intervention Increases PrEP Drug Levels in a Real World Setting - (03/10/17) The Challenges of Translating PrEP Interest into Uptake among Young Black MSM in Atlanta, GA - (03/10/17) Biological-vs-Chronological Age Difference Significantly Greater With HIV - Mark Mascolini (03/08/17) Novel Imaging Strategy Shows High-Level Aortic CD206+ Macrophage Infiltration in HIV ......CVD risk / inflammation - (03/08/17) BONE DENSITY, MICROARCHITECTURE, AND BONE STRENGTH AFTER 1 YEAR OF TDF - (03/08/17) CHANGES IN THE ORAL MICROBIOME WITH ART INITIATION / Microbiome Affects of Low Baseline CD4/High Viral Load - (03/08/17) A Systematic HCV-RNA Screening in HIV+ MSM Reveals a High Number of Potential Transmitters: 5% HCV Prevalence, 17% acute HCV incidence, higher rates of condomless sex, IDU, syphillis - (03/07/17) High and Rising HCV Incidence in San Diego Study of 2395 MSM With HIV - Mark Mascolini (03/07/17) The Association Between HCV And Comorbid Conditions In 2 Large Patient Cohorts - (03/07/17) Bone density and trabecular bone score improve fracture prediction in HIV-infected women - (03/06/17) Bone Micro-Architectural Changes and Fracture Risk Prediction in HIV and HCV - (03/06/17) CANCER INCIDENCE AMONG PERSONS ON MODERN SUPPRESSIVE ANTIRETROVIRAL THERAPY, 2000-12 - (03/06/17) Cancer risk among HIV-infected people in the U.S. during the modern treatment era - (03/06/17) LOW PREVALENCE OF HIV DRUG RESISTANCE WITH MODERN AGENTS - (03/06/17) INCREASED PERSISTENCE OF INITIAL ART WITH INSTI-CONTAINING REGIMENS - (03/06/17) A Phase 2 Open-Label Trial of Antibody UB-421 Monotherapy as a Substitute for HAART - (03/06/17) Cognitive Complaints and Development of Falls among HIV-Infected and Uninfected Women - (03/06/17) A Comparison of Fracture Risk Estimates in HIV-positive and HIV-negative Subjects; Data from HIV UPBEAT (Understanding the Pathology of Bone Disease in HIV-infected Subjects) - (03/06/17) The Effect of ART on Inflammation, Coagulation and Vascular Injury in START..... "Immediate ART led to reductions at 8 months of 12-21% in D-dimer, IL-6, SAA, sICAM and sVCAM levels compared with deferral of ART.".....likely reducing risk for comorbidities - (03/06/17) Association of Inflammation and Coagulation with Clinical Risk in the START Trial ...... - (03/06/17) The Association Between HCV And Comorbid Conditions In 2 Large Patient Cohorts - Mark Mascolini - (03/02/17) High prevalence of hepatitis C virus among HIV negative MSM in the Amsterdam PrEP project - (03/02/17) HCC DEVELOPMENT IN HCV PATIENTS AFTER DAA: THE EXPERIENCE OF THE SCOLTA PROJECT - (03/02/17) Liver Cancer Cases Rise After SVR With All-DAA Therapy in Spanish HCV/HIV Cohort...... "our study has not found evidence for an increased HCC incidence with DAA use" - Mark Mascolini - (03/02/17) Unrestricted Dutch Athena Cohort (HIV+/MSM/IDU) DAA Access Leads to Speedy Uptake, High Cure Rates ....'51% decrease in acute HCV, increased STD rates/syphillis' - Mark Mascolini - (03/02/17) High and Rising HCV Incidence in San Diego Study of 2395 MSM With HIV - Mark Mascolini - (03/02/17) No Evidence of Ongoing HIV Replication After 7 Years on ART.....but clonal expansion persists/HIV-Cure implications - (03/02/17) Impact of antiretroviral treatment containing tenofovir difumarate on the telomere length of aviremic HIV-infected patients / NRTIs, HIV & Telomerase, Aging, Comorbidities - (03/02/17) Leukocyte Telomere Attrition is Rapid Following HIV but not HCV Seroconversion - (03/02/17) Telomere length: neurocognitive biomarker in HIV-1-infected subjects - (03/02/17) Elsulfavirine as Compared to Efavirenz in Combination with TDF/FTC: 48-week Study - (03/02/17) Factors associated with rapid eGFR decline while receiving TDF and/or ATV - (03/02/17) Current Statin Use Reduces Risk of Viral Rebound on Suppressive cART - (03/02/17) Effect of cobicistat on tenofovir plasma concentrations: a cross-sectional study - (03/02/17) Crushing of dolutegravir combination tablets increases dolutegravir exposure - (03/02/17) HUMAN CONFIRMATION OF ORAL DOSE REDUCTION POTENTIAL OF NANOPARTICLE ANTIRETROVIRAL FORMULATIONS - (03/02/17) Long Acting HIV ART - is this the future? Nanoformulations - Implants - (03/02/17) A Bi-Specific Approach for Targeting IMRs in HIV-1 Latency - (03/02/17) IMPAACT P1110: RALTEGRAVIR PHARMACOKINETICS AND SAFETY IN HIV-1 EXPOSED NEONATES: DOSE-FINDING STUDY - (03/02/17) Bictegravir Dissociation Half-life from HIV-1 G140S/Q148H Integrase-DNA Complexes - (03/02/17) CEREBRAL SMALL-VESSEL DISEASE IN HIV-INFECTED PATIENTS WELL CONTROLLED ON cART - (03/02/17) PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update - (03/01/17) CEREBRAL SMALL VESSEL DISEASE IN cART WELL-CONTROLLED HIV-INFECTED PATIENTS ANRS EP51 MICROBREAK - (02/28/17) Novel HIV PI with High Resistance Barrier and Potential for Unboosted QD Oral Dosing - (02/28/17) CEREBRAL SMALL VESSEL DISEASE IN cART WELL-CONTROLLED HIV-INFECTED PATIENTS ANRS EP51 MICROBREAK - (02/28/17) Bictegravir Dissociation Half-life from HIV-1 G140S/Q148H Integrase-DNA Complexes - (02/28/17) CEREBRAL SMALL-VESSEL DISEASE IN HIV-INFECTED PATIENTS WELL CONTROLLED ON cART - (02/28/17) PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update - (02/28/17) Novel Non-Catalytic Site Integrase Inhibitor with Improved Resistance Profile - (02/28/17) Efficacy and Safety of Switching to E/C/F/TAF in Virologically Suppressed Women - (02/26/17) CDC - HIV Incidence, Prevalence and Undiagnosed Infections in Men Who Have Sex With Men - HIV incidence decreased among all transmission categories except MSM - (02/26/17) Viral Suppression in NYC, NYS, and LA - (02/26/17) Frailty Stronger Than Neurocognitive Impairment in Predicting Falls-Disability-Death - Mark Mascolini - (02/26/17) Non-AIDS Illness Burden Differs by Sex, Race, and Insurance Type in Aging HIV+ Adults - HOPS - Number of Comorbidities Double from 45 to 60 Years Old/Blacks Disproportionately Affected - (02/26/17) LONGITUDINAL VIRAL TRAJECTORY AMONG WOMEN IN THE WOMEN'S INTERAGENCY HIV STUDY - (02/26/17) Time spent with HIV viral load >1500 copies/mL among patients in HIV care, 2000-2014....viral suppression and early HAART start are top federal priority - (02/26/17) Ending HIV Epidemic in NYC - Plan/Strategy IF YOU CAN MAKE IT THERE: ENDING THE HIV EPIDEMIC IN NEW YORK - (02/26/17) INCIDENCE OF HEPATITIS C AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN IN SAN DIEGO, 2000-2015 - (02/24/17) Pharmacokinetics of Total and Unbound Rilpivirine in HIV-1-infected Pregnant Women - (02/24/17) HPTN 076: TMC278 LA Safe, Tolerable and Acceptable for HIV Pre-Exposure Prophylaxis - (02/24/17) LONGITUDINAL ASSESSMENT OF REGIONALLY SPECIFIC BRAIN VOLUMES IN TREATED HIV+ PATIENTS - (02/24/17) IMPACT OF ADVANCING AGE ON COGNITION IN HIV+ PERSONS ON A FIRST SUPPRESSIVE REGIMEN - (02/24/17) Cognitive Trajectories in Suppressed HIV Infection Indicate Evolving Disease Activity - (02/24/17) Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression: HIV+ virally suppressed had worse cognitive decline in 3 domains vs HIV-neg, 4 yrs followup - (02/24/17) BIOMARKERS OF AGEING IN HIV-POSITIVE INDIVIDUALS AND MATCHED CONTROLS: 8 years greater biologic age in HIV+ - (02/24/17) LONGITUDINAL ANALYSIS SHOWS NO EVIDENCE FOR ACCELERATED BRAIN AGEING IN TREATED HIV - (02/24/17) State-Level Estimates of HIV Incidence, Prevalence, and Undiagnosed Infections: 12.2% Undiagnosed in NYS; 15% US undiagnosed - (02/24/17) Antiviral Activity of EFdA [MK-8591] Against NRTI-Sensitive and -Resistant Strains of HIV-2 - (02/24/17) Dolutegravir Based cART in Vertically-HIV-1-Infected Adolescents in Real-Life Setting - (02/24/17) MK-8591 Concentrations at Sites of HIV Transmission and Replication - (02/23/17) A LONG-ACTING NANOFORMULATED CABOTEGRAVIR PRODRUG FOR IMPROVED ANTIRETROVIRAL THERAPY - (02/23/17) DOLUTEGRAVIR PHARMACOKINETICS, SAFETY AND EFFICACY IN HIV+ CHILDREN 2 TO <6 YEARS OLD - (02/23/17) Increased dolutegravir exposure in HIV patients switched from ritonavir to cobicistat - (02/23/17) GS-9131 is a Novel NRTI with Activity Against NRTI-Resistant HIV-1 - (02/23/17) STEADY-STATE PHARMACOKINETICS OF DOLUTEGRAVIR IN PEOPLE LIVING WITH HIV OVER THE AGE OF 60 YEARS - (02/23/17) EFFECT OF DOLUTEGRAVIR PLASMA CONCENTRATION ON CENTRAL NERVOUS SYSTEM SIDE EFFECTS - (02/23/17) Dolutegravir as Maintenance Monotherapy for HIV-1: a Randomized Clinical Trial - (02/23/17) Promising Results of Lamivudine + Dolutegravir Maintenance Therapy in ANRS 167 Lamidol Trial - (02/23/17) TLR9 AGONIST TRIGGERS POTENT INTESTINAL ANTIVIRAL RESPONSE IN HIV+ INDIVIDUALS ON ART - (02/23/17) TLR7 Agonist Treatment of SIV+ Monkeys on ART Can Lead to Complete Viral Remission - (02/23/17) TLR7 Agonist GS-986 Markedly Activates T & B Cells From ART-suppressed Donors - (02/23/17) TLR7 Agonist GS-9620 (Vesatolimod) Increases Immune-Mediated Clearance of HIV-Infected Cells - (02/23/17) HIV Integrase Genotypic Testing and Resistance in the United States-9 U.S. Jurisdictions - (02/22/17) The Emerging Potential for HIV Cure for Infants, Children, and Adults - and - ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV - (02/22/17) Cessation of cigarette smoking and the impact on cancer incidence in the D:A:D Study - (02/22/17) US HIV Incidence Falling in All Transmission Risk Groups Except MSM - Mark Mascolini - (02/22/17) Frailty Stronger Than Neurocognitive Impairment in Predicting Falls-Disability-Death - Mark Mascolini - (02/22/17) No HIV Evolution in CHER Children With Viral Control Through 7 Years of ART - Mark Mascolini - (02/22/17) Monoclonal Antibody to IL-1beta Cuts Arterial Inflammation in 10 HIV Patients - Mark Mascolini - (02/22/17) Higher Bilirubin Tied to Lower CVD Risk in Veterans With or Without HIV - Mark Mascolini - (02/22/17) Age, Weight, Being a Woman Tied to Falls in Veterans With/Without HIV - Mark Mascolini - (02/22/17) Nonlung Cancer Incidence Drops Quickly After Smoking Stops in HIV Group - Mark Mascolini - (02/22/17) Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors - D:A:D (02/22/17) Oral Session Thursday: INFLAMMATION AND AGE-RELATED COMPLICATIONS - (02/20/17) Correlation of Renal Biomarkers and Tenofovir AUC in the ION-4 Study Cohort - (02/20/17) GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS - (02/20/17) Psychiatric Disorders Observed in HIV+ Patients Using 6 Common 3rd Agents in OPERA - (02/20/17) Neuropsychiatric Adverse Events Associated With Integrase Strand Transfer Inhibitors - (02/20/17) Discontinuation of DTG, EVG/c, and RAL due to toxicity in a prospective cohort - (02/20/17) Hyperbilirubinemia prevents cardiovascular disease for HIV+ and HIV-individuals - (02/20/17) Darunavir/r Use and Incident Chronic Kidney Disease in HIV-positive Persons - study found increased CKD risk with ATV but not with Darunavir - D:A:D Cohort - (02/20/17) Oral Session Thursday: INFLAMMATION AND AGE-RELATED COMPLICATIONS - 4 studies (1) Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors (2) Smoking Cessation & Impact on Cancers & Lung Cancer Risks in HIV+ (3) New CVD Anti-Inflammatory in Pilot Study in HIV+ (4) Hyperbillirubinemia Prevents CVD Risk - (02/20/17) Acute infection with a wild-type HIV-1 virus in a PrEP user with high TDF levels - (02/20/17) Correlation of Renal Biomarkers and Tenofovir AUC in the ION-4 Study Cohort - (02/19/17) Frailty Progression and Recovery among Persons Aging with HIV and Substance Use - (02/18/17) HIV RNA Rebound Post-Interruption in Persons Suppressed in Fiebig I Acute HIV - (02/18/17) EPICARDIAL FAT, IMMUNE ACTIVATION, AND CORONARY PLAQUE AMONG HIV+ AND HIV- WOMEN - (02/18/17) APPLES - The Australian Positive & Peers Longevity Evaluation Study - (02/18/17) Identification of Latency Reversing Agents (LRAs) Active in Diverse Primary T-cell Models of HIV Latency - (02/18/17) Long-term Safety and Efficacy of CAB and RPV as 2-Drug Oral Maintenance Therapy - (02/18/17) Nonlung Cancer Incidence Drops Quickly After Smoking Stops in HIV Group - written by Mark Mascolini - (02/18/17) Cardiovascular Risk as Great With Darunavir as With Indinavir or Lopinavir - written by Mark Mascolini - (02/18/17) Less Inflammation Tied to Lower Frailty Progression, Greater Frailty Recovery - written by Mark Mascolini - (02/18/17) Earlier [cd4 350-500] Versus Delayed Antiretroviral Therapy Initiation and Risk of Cancer - written by Mark Mascolini - (02/18/17) The Large Gap Between Statin Eligibility and Prescription in the NA-ACCORD - written by Mark Mascolini - (02/18/17) Persistent Immune Activation Despite ART: The "Die is Cast" Before ART Initiation - (02/16/17) On Demand Post-Exposure Prophylaxis with Doxycycline for MSM Enrolled in a PrEP Trial - (02/16/17) On Demand Post-Exposure Prophylaxis with Doxycycline for MSM Enrolled in a PrEP Trial - (02/16/17) GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS - (02/16/17) Higher Rates of Heart Disease, Diabetes, Neuropathy in Older Men With vs Without HIV - written by Mark Mascolini - (02/16/17) PEP With Doxycycline Halves Bacterial STI Rate in MSM on TDF/FTC PrEP - written by Mark Mascolini - (02/16/17) "Critical Barrier" Between PrEP Interest and Uptake in Young Black MSM - written by Mark Mascolini - (02/16/17) HIV Compartmentalization in Central Nervous System During Acute Infection - written by Mark Mascolini - (02/16/17) HIV More Than Doubles Odds of Cerebral Small-Vessel Disease in French Study - written by Mark Mascolini - (02/16/17) Viral Load Undetectable 288 Days Without ART After Stem Cell Transplant - written by Mark Mascolini - (02/16/17) Steady Drop in Time Spent With Viral Load Above 1500 Copies in US Group - written by Mark Mascolini - (02/16/17) Significant Efficacy and Long-term Safety Difference With TAF-Based STR in Naïve Adults - (02/16/17) 288 Day Drug-Free Remission From HIV Rebound by Allogeneic PBSCT - (02/16/17) Longitudinal HIV Viral Trajectories and Co-Morbidities Longitudinal in the WIHS: Viral Suppression Key to Survival - (02/16/17) Long-Term Efficacy of Dolutegravir 50 mg BID in INI-Resistant Failing HIV-1 Subjects - (02/16/17) HIV Attachment Inhibitor Fostemsavir / BMS-663068, GSK3684934 - (02/16/17) In Vitro -In Vivo Evaluation of a Biodegradable Implant Containing TAF for HIV PrEP - (02/16/17) LONG-ACTING IBALIZUMAB IN PATIENTS WITH MULTI-DRUG RESISTANT HIV-1: A 24-WEEK STUDY - (02/16/17) Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab - (02/16/17) DORAVIRINE IS NON-INFERIOR TO DARUNAVIR+RITONAVIR IN PHASE 3 TREATMENT-NAïVE TRIAL AT WEEK 48 - (02/16/17) Discovery of Novel Potent HIV Capsid Inhibitors with Long-Acting Potential - (02/16/17) Viral Load Dynamics Among Persons with Diagnosed HIV: United States, 2014 - (02/16/17) PREVALENCE AND IMPACT OF PRETREATMENT DRUG RESISTANCE IN 12249 TREATMENT AS PREVENTION TRIAL - (02/16/17) Doravirine in Non-Inferior To Darunavir+Ritonavir in Phase 3 Treatment-Naive Trial at Week 48 - (02/16/17) Clinical Pharmacology of the Unboosted HIV Integrase Strand Transfer Inhibitor (INSTI) Bictegravir (BIC) - (02/16/17) Randomized Trial of Bictegravir or Dolutegravir with FTC/TAF for Initial HIV Therapy - (02/16/17) SWORD 1 & 2: Switch to DTG + RPV Maintains Virologic Suppression Through 48 Weeks, a Phase III Study - (02/16/17) Inflammation and Coagulation Markers Predict Clinical Risk in START Trial - written by Mark Mascolini - (02/15/17) Excess Epicardial Fat Tied to Noncalcified Plaque in Women With HIV - written by Mark Mascolini - (02/15/17) Cardiovascular Risk More Likely With Longer Viral Control in WIHS Women - written by Mark Mascolini - (02/15/17) Monoclonal Antibody Suppresses HIV in Half With Multidrug-Resistant Virus - written by Mark Mascolini - (02/15/17) New Integrase Inhibitor Attains 97% Viral Suppression Through 48 Weeks - written by Mark Mascolini - (02/15/17) Only Half of Big US HIV Group Had Durable Viral Suppression in 2014 - written by Mark Mascolini - (02/15/17) Three in 30 Infants Treated in First 48 Hours of Life Become PCR Negative - written by Mark Mascolini - (02/15/17) ViiV Announces SWORD Study Results: Dolutegravir+Rilpivirine in Virologically Suppressed - (02/14/17) Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors - (02/14/17) Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV - (02/14/17)